Quantinno Capital Management LP Sells 6,501 Shares of Encompass Health Corporation $EHC

Quantinno Capital Management LP trimmed its stake in shares of Encompass Health Corporation (NYSE:EHC) by 7.6% during the first quarter, HoldingsChannel reports. The fund owned 78,669 shares of the company’s stock after selling 6,501 shares during the period. Quantinno Capital Management LP’s holdings in Encompass Health were worth $7,610,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of EHC. EP Wealth Advisors LLC raised its stake in shares of Encompass Health by 2.4% during the 2nd quarter. EP Wealth Advisors LLC now owns 3,694 shares of the company’s stock worth $453,000 after purchasing an additional 88 shares in the last quarter. Gamco Investors INC. ET AL lifted its position in Encompass Health by 2.0% during the first quarter. Gamco Investors INC. ET AL now owns 4,813 shares of the company’s stock worth $466,000 after acquiring an additional 94 shares during the last quarter. Gibson Capital LLC lifted its holdings in Encompass Health by 4.3% during the 1st quarter. Gibson Capital LLC now owns 2,431 shares of the company’s stock worth $235,000 after purchasing an additional 101 shares during the last quarter. Leuthold Group LLC lifted its holdings in shares of Encompass Health by 0.3% during the fourth quarter. Leuthold Group LLC now owns 31,168 shares of the company’s stock worth $3,308,000 after buying an additional 104 shares in the last quarter. Finally, Covestor Ltd raised its stake in Encompass Health by 24.4% in the 4th quarter. Covestor Ltd now owns 540 shares of the company’s stock worth $57,000 after purchasing an additional 106 shares in the last quarter. Institutional investors own 97.25% of the company’s stock.

Encompass Health Trading Up 0.0%

NYSE:EHC opened at $110.55 on Thursday. The stock’s fifty day moving average price is $106.14 and its two-hundred day moving average price is $104.27. The company has a market cap of $10.97 billion, a P/E ratio of 18.46, a P/E/G ratio of 2.41 and a beta of 0.72. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.17 and a quick ratio of 1.17. Encompass Health Corporation has a 1 year low of $92.77 and a 1 year high of $127.99.

Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.48 by $0.07. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.57 billion. Encompass Health had a net margin of 10.04% and a return on equity of 18.28%. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period last year, the firm earned $1.40 EPS. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. As a group, analysts expect that Encompass Health Corporation will post 5.96 EPS for the current year.

Encompass Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be paid a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.8%. This is an increase from Encompass Health’s previous quarterly dividend of $0.19. The ex-dividend date of this dividend is Thursday, October 1st. Encompass Health’s payout ratio is 12.69%.

Analyst Ratings Changes

EHC has been the subject of several recent analyst reports. Barclays cut their price objective on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a research report on Tuesday, May 5th. TD Cowen began coverage on Encompass Health in a research note on Thursday, May 28th. They issued a “buy” rating and a $125.00 price objective on the stock. Wall Street Zen raised Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Leerink Partners set a $152.00 target price on Encompass Health in a report on Friday, May 22nd. Finally, Weiss Ratings downgraded Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $143.86.

Insider Transactions at Encompass Health

In other news, EVP Patrick William Tuer sold 682 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $104.56, for a total value of $71,309.92. Following the transaction, the executive vice president owned 24,755 shares in the company, valued at approximately $2,588,382.80. This trade represents a 2.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.80% of the stock is currently owned by insiders.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.